Trials / Unknown
UnknownNCT03535415
A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Short Stature Children Due to Chronic Kidney Disease Before Transplantation
A Phase 3 Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Short Stature Children Due to Chronic Kidney Disease Before Transplantation
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 68 (estimated)
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 2 Years – 14 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the efficacy and safety of recombinant human growth hormone injection in short stature children due to chronic kidney disease before transplantation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Recombinant Human Growth Hormone Injection (rhGH) | rhGH 0.05mg/kg/d by subcutaneous injection |
Timeline
- Start date
- 2018-06-25
- Primary completion
- 2020-09-01
- Completion
- 2021-09-01
- First posted
- 2018-05-24
- Last updated
- 2018-11-23
Locations
12 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03535415. Inclusion in this directory is not an endorsement.